Difference between revisions of "Bortezomib (Velcade)"
Jump to navigation
Jump to search
m |
m (antiviral prophylaxis recommendation) |
||
| Line 5: | Line 5: | ||
<br>Route: IV, SC | <br>Route: IV, SC | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| + | |||
| + | *Use antiviral prophylaxis to decrease risk of reactivating herpes zoster in patients treated with Bortezomib (Velcade) | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. | ||
Revision as of 14:07, 12 March 2012
Also known as PS-341.
General information
Class/mechanism: Reversible inhibitor of the 26S proteasome, interfering with degradation of ubiquitinated proteins. This disrupts normal homeostatic mechansims, leading to cell death.[1][2]
Route: IV, SC
Extravasation: irritant
- Use antiviral prophylaxis to decrease risk of reactivating herpes zoster in patients treated with Bortezomib (Velcade)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Bortezomib (Velcade) patient drug information (Chemocare)[3]
- Bortezomib (Velcade) patient drug information (UpToDate)[4]